These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 33327495

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAFV600E mutation bearing metastatic melanoma cells.
    Carpenter EL, Chagani S, Nelson D, Cassidy PB, Laws M, Ganguli-Indra G, Indra AK.
    Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines.
    Herr R, Halbach S, Heizmann M, Busch H, Boerries M, Brummer T.
    Oncogene; 2018 Mar; 37(12):1576-1593. PubMed ID: 29326440
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
    Brummer C, Faerber S, Bruss C, Blank C, Lacroix R, Haferkamp S, Herr W, Kreutz M, Renner K.
    Cancer Lett; 2019 Feb 01; 442():453-463. PubMed ID: 30481565
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells.
    Babagana M, Johnson S, Slabodkin H, Bshara W, Morrison C, Kandel ES.
    Mol Carcinog; 2017 May 01; 56(5):1515-1525. PubMed ID: 28052407
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma.
    Saei A, Eichhorn PJA.
    Mol Cell Oncol; 2018 May 01; 5(5):e1497862. PubMed ID: 30263945
    [Abstract] [Full Text] [Related]

  • 37. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
    Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS.
    Clin Cancer Res; 2013 Feb 01; 19(3):598-609. PubMed ID: 23095323
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
    Miao B, Ji Z, Tan L, Taylor M, Zhang J, Choi HG, Frederick DT, Kumar R, Wargo JA, Flaherty KT, Gray NS, Tsao H.
    Cancer Discov; 2015 Mar 01; 5(3):274-87. PubMed ID: 25542448
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.